PE20160156A1 - Derivados de prodroga de triazolpiridinas sustituidas - Google Patents
Derivados de prodroga de triazolpiridinas sustituidasInfo
- Publication number
- PE20160156A1 PE20160156A1 PE2015002605A PE2015002605A PE20160156A1 PE 20160156 A1 PE20160156 A1 PE 20160156A1 PE 2015002605 A PE2015002605 A PE 2015002605A PE 2015002605 A PE2015002605 A PE 2015002605A PE 20160156 A1 PE20160156 A1 PE 20160156A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- derivatives
- triazolpyridines
- prodrog
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06086—Dipeptides with the first amino acid being basic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
SE REFIERE A DERIVADOS SUSTITUIDOS DE 2-ANILINO-6-(4-{[(2R)-2-(4-FLUOROFENIL)PROPANOIL]AMINO}FENIL)[1, 2, 4]TRIAZOLO[1, 5-A]PIRIDINA DE FORMULA (I), EN DONDE RA ES -C(O)-(CH2)3-NH-C1-C6-ALQUILO, -C(O)O-(CH2)2-NH-C1-C6-ALQUILO, O -C(O)O-CH2-O-C(O)-C1-C6-ALQUILO, ENTRE OTROS; R1 ES METOXI O 2, 2, 2-TRIFLUOROETOXI; Y R2 ES -S(O)2-CH3, AZETIDIN-1-IL-CARBONILO, 3-FLUOROAZETIDIN-1-IL-CARBONILO O -C(O)-N(CH3)2. DICHOS COMPUESTOS SON INHIBIDORES DE LA QUINASA MPS-1, POR LO CUAL SON UTILES EN LA TERAPIA DE ENFERMEDADES RELACIONADAS CON UN CRECIMIENTO, PROLIFERACION O SUPERVIVENCIA CELULAR DESCONTROLADA, O CON UNA RESPUESTA INMUNE CELULAR INAPROPIADA, O CON UNA RESPUESTA INFLAMATORIA CELULAR INAPROPIADA, TALES COMO LAS LEUCEMIAS, LINFOMAS MALIGNOS, TUMORES CEREBRALES, TUMORES DE LAS CELULAS PULMONARES, ENTRE OTRAS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13171508 | 2013-06-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20160156A1 true PE20160156A1 (es) | 2016-04-20 |
Family
ID=48576905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2015002605A PE20160156A1 (es) | 2013-06-11 | 2014-06-06 | Derivados de prodroga de triazolpiridinas sustituidas |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US9586958B2 (es) |
| EP (1) | EP3008062B1 (es) |
| JP (1) | JP2016526534A (es) |
| KR (1) | KR20160019492A (es) |
| CN (1) | CN105377848A (es) |
| AP (1) | AP2015008898A0 (es) |
| AR (1) | AR096585A1 (es) |
| AU (1) | AU2014280356A1 (es) |
| CA (1) | CA2914745A1 (es) |
| CL (1) | CL2015003605A1 (es) |
| CR (1) | CR20150659A (es) |
| CU (1) | CU20150176A7 (es) |
| DK (1) | DK3008062T3 (es) |
| DO (1) | DOP2015000299A (es) |
| EA (1) | EA201600002A1 (es) |
| ES (1) | ES2626790T3 (es) |
| HK (1) | HK1221955A1 (es) |
| HR (1) | HRP20170717T1 (es) |
| HU (1) | HUE033131T2 (es) |
| IL (1) | IL242847A0 (es) |
| LT (1) | LT3008062T (es) |
| MA (1) | MA38654B1 (es) |
| MX (1) | MX2015017119A (es) |
| NI (1) | NI201500176A (es) |
| PE (1) | PE20160156A1 (es) |
| PH (1) | PH12015502746A1 (es) |
| PL (1) | PL3008062T3 (es) |
| PT (1) | PT3008062T (es) |
| RS (1) | RS56034B1 (es) |
| SG (1) | SG11201509858QA (es) |
| SI (1) | SI3008062T1 (es) |
| TN (1) | TN2015000545A1 (es) |
| UY (1) | UY35610A (es) |
| WO (1) | WO2014198647A2 (es) |
| ZA (1) | ZA201508868B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41136A (fr) * | 2014-12-09 | 2017-10-17 | Bayer Pharma AG | Composés pour le traitement d'un cancer |
| US11208696B2 (en) | 2015-04-17 | 2021-12-28 | Netherlands Translational Research Center B.V. | Prognostic biomarkers for TTK inhibitor chemotherapy |
| RU2748260C2 (ru) | 2016-04-04 | 2021-05-21 | Кемосентрикс, Инк. | РАСТВОРИМЫЕ С5аR АНТАГОНИСТЫ |
| AU2022408915A1 (en) * | 2021-12-15 | 2024-06-27 | Sillajen, Inc. | Methods of treating neoplastic diseases |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69736711T2 (de) | 1996-08-28 | 2007-09-20 | Pfizer Inc. | Substituierte 6,5-heterobicyclische-derivate |
| EP0991628B1 (en) | 1997-05-28 | 2005-01-12 | Aventis Pharmaceuticals Inc | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR P56lck TYROSINE KINASES |
| US6514989B1 (en) | 2001-07-20 | 2003-02-04 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives |
| JP2004346016A (ja) | 2003-05-22 | 2004-12-09 | Otsuka Chemical Co Ltd | トリフルオロメチルキノキサリン化合物、その製造方法、及び有害生物防除剤 |
| EP1646382A4 (en) | 2003-06-30 | 2010-07-21 | Hif Bio Inc | COMPOUNDS, COMPOSITIONS AND METHODS |
| JP2008515874A (ja) | 2004-10-07 | 2008-05-15 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | 抗菌薬 |
| WO2007025090A2 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase |
| US20070078136A1 (en) | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| US7723336B2 (en) | 2005-09-22 | 2010-05-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| WO2007065010A2 (en) | 2005-12-02 | 2007-06-07 | Hif Bio, Inc. | Anti-angiogenesis compounds |
| NZ573015A (en) | 2006-05-31 | 2010-11-26 | Galapagos Nv | Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases |
| WO2008021389A2 (en) | 2006-08-16 | 2008-02-21 | Exelixis, Inc. | Using pi3k and mek modulators in treatments of cancer |
| MX2009002171A (es) | 2006-08-30 | 2009-05-28 | Cellzome Ltd | Derivados de triazol como inhibidores de cinasas. |
| US7592342B2 (en) | 2007-05-10 | 2009-09-22 | Smithkline Beecham Corporation | Quinoxaline derivatives as PI3 kinase inhibitors |
| AU2008277628B2 (en) | 2007-07-18 | 2012-03-15 | Novartis Ag | Bicyclic heteroaryl compounds and their use as kinase inhibitors |
| EP2173354A4 (en) | 2007-08-09 | 2011-10-05 | Glaxosmithkline Llc | CHINOXALIN DERIVATIVES AS PI3 KINASE INHIBITORS |
| CN103298814A (zh) | 2007-08-23 | 2013-09-11 | 阿斯利康(瑞典)有限公司 | 作为治疗增殖性疾病的ttk/mps1抑制剂的2-苯胺基嘌呤-8-酮 |
| KR20100075881A (ko) | 2007-08-31 | 2010-07-05 | 메르크 세로노 에스. 에이. | 트리아졸로피리딘 화합물 및 ａｓｋ 저해제로서 이의 용도 |
| GB0719803D0 (en) | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| WO2009068482A1 (en) | 2007-11-27 | 2009-06-04 | Cellzome Limited | Amino triazoles as pi3k inhibitors |
| WO2009155121A2 (en) | 2008-05-30 | 2009-12-23 | Amgen Inc. | Inhibitors of pi3 kinase |
| TWI491610B (zh) | 2008-10-09 | 2015-07-11 | 必治妥美雅史谷比公司 | 作為激酶抑制劑之咪唑并嗒腈 |
| WO2010092015A1 (en) | 2009-02-10 | 2010-08-19 | Cellzome Limited | Urea triazololo [1, 5-a] pyridine derivatives as pi3k inhibitors |
| CA2751517A1 (en) | 2009-02-13 | 2010-08-19 | Fovea Pharmaceuticals | [1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors |
| EP2424537B1 (en) | 2009-04-29 | 2015-07-08 | Bayer Intellectual Property GmbH | Substituted imidazoquinoxalines |
| TW201107329A (en) | 2009-07-30 | 2011-03-01 | Oncotherapy Science Inc | Fused imidazole derivative having ttk inhibitory action |
| EP2473498A1 (en) | 2009-09-04 | 2012-07-11 | Bayer Pharma Aktiengesellschaft | Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors |
| EP2343294A1 (en) * | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Substituted triazolopyridines |
| EP2343297A1 (en) * | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridines |
| EP2343295A1 (en) * | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridine derivates |
| US9145399B2 (en) | 2010-01-15 | 2015-09-29 | Janssen Pharmaceuticals, Inc. | Substituted bicyclic triazole derivatives as gamma secretase modulators |
| US20110190269A1 (en) | 2010-02-01 | 2011-08-04 | Karlheinz Baumann | Gamma secretase modulators |
| UY33452A (es) * | 2010-06-16 | 2012-01-31 | Bayer Schering Pharma Ag | Triazolopiridinas sustituidas |
| TWI541243B (zh) | 2010-09-10 | 2016-07-11 | 拜耳知識產權公司 | 經取代咪唑并嗒 |
| AU2012244859B2 (en) * | 2011-04-21 | 2017-06-08 | Bayer Intellectual Property Gmbh | Triazolopyridines |
| UA112096C2 (uk) * | 2011-12-12 | 2016-07-25 | Байєр Інтеллектуал Проперті Гмбх | Заміщені триазолопіридини та їх застосування як інгібіторів ttk |
| CA2867061A1 (en) | 2012-03-14 | 2013-09-19 | Bayer Intellectual Property Gmbh | Substituted imidazopyridazines |
| JP6238979B2 (ja) * | 2012-07-10 | 2017-11-29 | バイエル・ファルマ・アクティエンゲゼルシャフト | 置換トリアゾロピリジンを調製する方法 |
| AR096469A1 (es) * | 2013-06-06 | 2015-12-30 | Bayer Pharma AG | Composiciones farmacéuticas que comprenden compuestos del tipo triazolpiridinas |
| WO2014195276A1 (en) * | 2013-06-07 | 2014-12-11 | Bayer Pharma Aktiengesellschaft | Substituted triazolopyridines having activity as mps-1 inhibitors |
| CN105246891A (zh) * | 2013-06-10 | 2016-01-13 | 拜耳制药股份公司 | 用于治疗癌症的新化合物 |
| US20160128988A1 (en) * | 2013-06-11 | 2016-05-12 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor |
-
2014
- 2014-06-06 DK DK14728949.0T patent/DK3008062T3/en active
- 2014-06-06 JP JP2016518941A patent/JP2016526534A/ja active Pending
- 2014-06-06 MX MX2015017119A patent/MX2015017119A/es unknown
- 2014-06-06 HU HUE14728949A patent/HUE033131T2/en unknown
- 2014-06-06 MA MA38654A patent/MA38654B1/fr unknown
- 2014-06-06 SI SI201430219A patent/SI3008062T1/sl unknown
- 2014-06-06 LT LTEP14728949.0T patent/LT3008062T/lt unknown
- 2014-06-06 AP AP2015008898A patent/AP2015008898A0/xx unknown
- 2014-06-06 KR KR1020167000270A patent/KR20160019492A/ko not_active Withdrawn
- 2014-06-06 PL PL14728949T patent/PL3008062T3/pl unknown
- 2014-06-06 CN CN201480040729.XA patent/CN105377848A/zh active Pending
- 2014-06-06 HK HK16110219.6A patent/HK1221955A1/zh unknown
- 2014-06-06 AU AU2014280356A patent/AU2014280356A1/en not_active Abandoned
- 2014-06-06 CA CA2914745A patent/CA2914745A1/en not_active Abandoned
- 2014-06-06 EA EA201600002A patent/EA201600002A1/ru unknown
- 2014-06-06 SG SG11201509858QA patent/SG11201509858QA/en unknown
- 2014-06-06 PE PE2015002605A patent/PE20160156A1/es not_active Application Discontinuation
- 2014-06-06 RS RS20170534A patent/RS56034B1/sr unknown
- 2014-06-06 PT PT147289490T patent/PT3008062T/pt unknown
- 2014-06-06 TN TN2015000545A patent/TN2015000545A1/en unknown
- 2014-06-06 US US14/897,951 patent/US9586958B2/en not_active Expired - Fee Related
- 2014-06-06 ES ES14728949.0T patent/ES2626790T3/es active Active
- 2014-06-06 HR HRP20170717TT patent/HRP20170717T1/hr unknown
- 2014-06-06 WO PCT/EP2014/061779 patent/WO2014198647A2/en not_active Ceased
- 2014-06-06 EP EP14728949.0A patent/EP3008062B1/en active Active
- 2014-06-11 AR ARP140102239A patent/AR096585A1/es unknown
- 2014-06-11 UY UY0001035610A patent/UY35610A/es not_active Application Discontinuation
-
2015
- 2015-11-30 IL IL242847A patent/IL242847A0/en unknown
- 2015-12-03 ZA ZA2015/08868A patent/ZA201508868B/en unknown
- 2015-12-09 PH PH12015502746A patent/PH12015502746A1/en unknown
- 2015-12-11 CU CUP2015000176A patent/CU20150176A7/es unknown
- 2015-12-11 CL CL2015003605A patent/CL2015003605A1/es unknown
- 2015-12-11 DO DO2015000299A patent/DOP2015000299A/es unknown
- 2015-12-11 NI NI201500176A patent/NI201500176A/es unknown
- 2015-12-11 CR CR20150659A patent/CR20150659A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR095311A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
| PE20191613A1 (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret | |
| PE20191245A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim | |
| CO6440524A2 (es) | Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la quinasa janus. | |
| EA202090291A3 (ru) | Производные бипиразола в качестве ингибиторов jak | |
| PE20121815A1 (es) | Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6 | |
| MX2022001343A (es) | Compuestos y composiciones para tratar trastornos hematologicos. | |
| CO2018002829A2 (es) | Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) | |
| ECSP088121A (es) | Derivados de pirrolo [2,3-b] piridina comoinhibidores de proteina cinasa | |
| ECSP088145A (es) | Derivados bicíclicos como inhibidores de la cinasa p38 | |
| PE20090506A1 (es) | DERIVADOS DE IMIDAZO-[1,2-b]-PIRIDAZIN COMO INHIBIDORES DE ALK5 Y/O ALK4 | |
| CO2018011408A2 (es) | Compuestos de pirimidina como inhibidores de la quinasa jak | |
| NI201100063A (es) | Inhibidores de las enzimas de proteína cinasa activadas por mitógeno p38. | |
| NI200700058A (es) | Compuestos de aminoheteroarilo sustituidos con pirazol como inhibidores de proteína quinasa | |
| SA520411638B1 (ar) | Tam أملاح لمشتقات بيرولو ترايازين مفيدة كمثبطات لـ | |
| ECSP13012596A (es) | Proceso de elaboración para derivados de pirimidina | |
| PE20130012A1 (es) | Derivados de pirazol como inhibidores de jak | |
| PE20170663A1 (es) | Compuestos de 5- cloro- 2- difluorometoxifenil pirazolopirimidina, composiciones y metodos de uso de los mismos | |
| PE20160747A1 (es) | Derivados heterociclicos inhibidores de la quinasa mps-1 | |
| GT201600091A (es) | Derivados de purina 2, 6-sustituidos y su uso en el tratamiento de trastornos proliferativos | |
| UA120065C2 (uk) | 4,6-ЗАМІЩЕНІ ПІРАЗОЛО[1,5-a]-ПІРАЗИНИ ЯК ІНГІБІТОРИ JAK-КІНАЗИ | |
| PE20180279A1 (es) | Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak | |
| PE20141351A1 (es) | Triazolopiridinas | |
| AR102171A1 (es) | Compuestos sustituidos de aminopurina, sus composiciones y su uso en el tratamiento o prevención de melanoma | |
| EA201390010A1 (ru) | Замещенные триазолопиридины |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |